Cerus Corporation (CERS)
| Market Cap | 522.96M +107.0% |
| Revenue (ttm) | 216.56M +17.0% |
| Net Income | -9.55M |
| EPS | -0.05 |
| Shares Out | 200.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,201,379 |
| Open | 2.610 |
| Previous Close | 2.610 |
| Day's Range | 2.480 - 2.660 |
| 52-Week Range | 1.150 - 3.150 |
| Beta | 1.62 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+53.26%) |
| Earnings Date | Apr 30, 2026 |
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma do... [Read more]
Financial Performance
In 2025, Cerus's revenue was $206.13 million, an increase of 14.35% compared to the previous year's $180.27 million. Losses were -$15.63 million, -25.29% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for CERS stock is "Strong Buy" and the 12-month stock price target is $4.0.
News
Cerus management to meet with Craig-Hallum
Meeting to be held in Chicago and Milwaukee on May 14 hosted by Craig-Hallum.
Cerus upgraded to Buy from Neutral at BTIG
BTIG upgraded Cerus (CERS) to Buy from Neutral with a $4 price target
Cerus Earnings Call Transcript: Q1 2026
Q1 2026 saw 24% product revenue growth, driven by strong platelet and IFC demand, with raised full-year guidance and continued margin discipline. Innovation and new contracts in the U.S. and EMEA support long-term growth, despite inflation and regulatory uncertainties.
Cerus reports Q1 EPS (1c), consensus (4c)
Reports Q1 revenue $59.9M, consensus $51.18M. “We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our
Cerus raises FY26 product revenue view to $227M-$231M from $224M-$228M
Consensus $233.9M.
Cerus Corporation Announces First Quarter 2026 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update. “We delivered a strong ...
Cerus announces new, four-year supply agreement with EFS
Cerus (CERS) Corporation announced the signing of a new, four-year supply agreement with Etablissement Francais du Sang, EFS, the French Blood Establishment, for the INTERCEPT Blood System. The agreem...
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establis...
Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the st...
Cerus names Vivek Jayaraman as CEO
Cerus (CERS) “announced that Vivek Jayaraman, Cerus’ chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William “Obi” Greenman will become exec...
Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effe...
Cathie Wood’s ARK Investment buys 612K shares of Cerus today
20:54 EST Cathie Wood’s ARK Investment buys 612K shares of Cerus (CERS) today
Cerus Transcript: TD Cowen 46th Annual Health Care Conference
INTERCEPT Blood System continues to expand its global leadership in transfusion safety, leveraging strong U.S. and international growth, a robust product pipeline, and strategic partnerships like the BCA agreement. Double-digit revenue growth is expected through 2026, with new product launches and geographic expansion driving future gains.
Cerus Earnings Call Transcript: Q4 2025
Record 2025 revenue and product growth were driven by strong U.S. and EMEA performance, successful INT200 launch, and expanding IFC adoption. 2026 guidance projects continued revenue and EBITDA growth, with BCA agreement and international expansion as key drivers.
Cerus reports Q4 EPS (1c), two estimates 0c
Reports Q4 revenueu $64.6M, consensus $59.31M. “Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world’s blood supply. This past
Cerus backs FY26 product revenue view $224M-$228M
The company expects full-year 2026 product revenue to be in the range of $224 million to $228 million, representing year-over-year growth of 9% to 11% compared to 2025 product revenue.
Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. “Our strong 2025 results reflect our ...
Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management are scheduled to present at the TD Cowen 46th Annual Health Care Conference ...
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of...
DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT™ Blood System in Routine Clinical Practice
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its sub...
Cerus reports preliminary Q4 revenue $57.8M, consensus $59.31M
“2025 was a remarkable year for Cerus (CERS), as patient access to INTERCEPT treated blood components increased meaningfully around the world,” said William “Obi” Greenman, Cerus’ president and chief ...
Cerus sees FY26 product revenue $224M-$228M
Looking ahead, the Company expects full-year 2026 product revenue to be in the range of $224 million to $228 million, representing year-over-year growth of 9%-11% compared to preliminary unaudited 202...
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided 2026 product revenue guida...
TD Cowen views Cerus’ IFC franchise as ‘underappreciated’ growth engine
TD Cowen says that Cerus (CERS)’ Intercept Fibrinogen Complex franchise represents an underappreciated long-term growth engine. The firm expects the newly announced BCA partnership to materially accel...
Cerus announces group purchasing pact with Blood Centers of America
Cerus (CERS) Corporation announced that it has entered into a group purchasing agreement with Blood Centers of America, the largest blood supply cooperative in the U.S. BCA member blood centers